On January 10, 2019, the FDA warned consumers not to use the weight loss supplement Slimina, because it was found to contain sibutramine.

Sibutramine, the active ingredient in the obesity drug Meridia, was removed from the U.S. market in October 2010 because it can substantially increase blood pressure and pulse rate in some individuals, and may present a significant risk for patients with a history of coronary artery disease, congestive heart failure, arrhythmias, or stroke. This drug may also interact, in life-threatening ways, with other medications a consumer may be taking.

Slimina is sold on various websites, including www.effectivehealthyproducts.com, and possibly in some retail stores.

Consumers who have purchased this supplement should not use it and contact their healthcare provider if they have experienced any adverse side effects. Consumers and healthcare providers are also encouraged to report any adverse reactions to the FDA's MedWatch Voluntary Reporting Program.

See ConsumerLab's Review of Weight Loss Supplements for tests of related products.

See Related Warnings:

Weight Loss Supplement Containing Hidden Drug Recalled

Pharmaceutical Drugs Found In Dietary Supplements Pose Danger to Consumers

Weight Loss Supplement Containing Undeclared Drug Recalled

Four Weight Loss Supplements Found To Contain Drugs

Weight Supplement Recalled

To read the full recall, use the link below.